These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 26650145)
1. Tiotropium Respimat Is Effective for the Treatment of Asthma at a Dose Lower Than That for Chronic Obstructive Pulmonary Disease. Chin SJ; Durmowicz AG; Chowdhury BA Ann Am Thorac Soc; 2016 Feb; 13(2):173-9. PubMed ID: 26650145 [TBL] [Abstract][Full Text] [Related]
2. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials. Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728 [TBL] [Abstract][Full Text] [Related]
3. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298 [TBL] [Abstract][Full Text] [Related]
4. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes. Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563 [TBL] [Abstract][Full Text] [Related]
5. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281 [TBL] [Abstract][Full Text] [Related]
6. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study. Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478 [TBL] [Abstract][Full Text] [Related]
9. Tiotropium Respimat inhaler and the risk of death in COPD. Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P; N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515 [TBL] [Abstract][Full Text] [Related]
10. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R; Kaplan A BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909 [TBL] [Abstract][Full Text] [Related]
11. The Respimat Soft Mist Inhaler, a Novel Inhaled Drug Delivery Device. Perriello EA; Sobieraj DM Conn Med; 2016; 80(6):359-64. PubMed ID: 27509644 [TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis. Konstan MW; Sharma A; Moroni-Zentgraf P; Wang F; Koker P J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):137-44. PubMed ID: 25380193 [TBL] [Abstract][Full Text] [Related]
14. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941 [TBL] [Abstract][Full Text] [Related]
16. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat Mansfield L; Duong-Quy S; Craig T Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830 [TBL] [Abstract][Full Text] [Related]
17. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491 [TBL] [Abstract][Full Text] [Related]
20. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]